US FDA And Congressional Oversight: Will Democrats Be Tougher Than The GOP?
Most US agencies can expect relatively friendly oversight from a Democratic Congress. The US FDA might be one exception, as a recent House hearing on foreign inspections shows.
You may also be interested in...
The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.
The oncology branch of the US FDA’s biologics center does not believe RTOR would speed application reviews.
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.